Zhao-Hui (Joe) Song Laboratory

About 

The current research focuses of Dr. Song’s laboratory are the molecular targets of cannabinoids. Cannabinoids are composed of three categories, including phytocannabinoids (the active chemical components of cannabis), endocannabinoids (the cannabinoid-like substances in our body), and synthetic cannabinoids. We are studying the ligand binding and signal transduction mechanisms of CB1 and CB2 cannabinoid receptors, two proven molecular targets for cannabinoids. In addition, we are investigating GPR3, GPR6 and GPR12, a family of orphan receptors that have been recently shown by us to be novel molecular targets for cannabidiol (CBD). CBD is the major non-psychoactive of marijuana and has been proposed to have therapeutic potentials for a variety of illnesses, including neurological/psychiatric disorders, substances use disorders, metabolic diseases and ocular diseases. Therefore, our research on molecular targets of CBD and other cannabinoids will not only help to understand the mechanisms of action for CBD, it will also explore the viability of these receptors as novel therapeutic targets.

Key Research Areas

  • Neurological/Psychiatric diseases/Neurodevelopmental disorders
  • Alcohol related liver disease, alcohol use disorders and other substance use disorders (e.g. opiate use disorders)
  • Ocular diseases

Current Projects

  • CBD as potential treatment for autism spectrum disorders: mechanisms and biomarkers
  • CBD as potential treatment for alcohol related liver disease and alcohol use disorders
  • Endocannabinoid system as novel therapeutic targets for ocular diseases
  • The therapeutic potential and mechanism of action for non-hallucinogenic psychedelics

Team 

Recent Publications

Zhao-Hui (Joe) Song Laboratory

Department of Pharmacology and Toxicology, School of Medicine

Website about

Location

Research Tower, 500 South Preston Street., Room A1305